Cancer Research Technology (CRT), the oncology-focused development and commercialisation company wholly owned by Cancer Research UK, today announce that they have entered into an agreement with Hammersmith Hospitals NHS Trust (London, UK) to develop Phased Array High-Intensity Focused Ultrasound (HIFU) for the treatment of cancer.
